EyePoint Pharmaceuticals Appoints Dr. Reginald J. Sanders to Board of Directors

EyePoint Pharmaceuticals appoints Dr. Reginald J. Sanders to its Board, enhancing leadership in retinal disease therapeutics development.

Quiver AI Summary

EyePoint Pharmaceuticals, Inc. has appointed Dr. Reginald J. Sanders, a prominent ophthalmologist and former president of the American Society of Retina Specialists, to its Board of Directors. Dr. Sanders is recognized for his extensive experience in retinal research and clinical practice, and he expressed enthusiasm about joining EyePoint at a pivotal time as the company advances its clinical trials for treatments targeting serious retinal diseases like wet age-related macular degeneration and diabetic macular edema. EyePoint's lead investigational product, DURAVYU, aims to provide sustained delivery treatment for these conditions and is currently undergoing global phase 3 trials. The company is optimistic about its innovative therapeutics pipeline and the potential impact of its treatments on patient care.

Potential Positives

• Appointment of Dr. Reginald J. Sanders, a distinguished leader in ophthalmology, to the Board of Directors enhances the company's scientific and medical leadership.
• Dr. Sanders' extensive experience and reputation in the retina community may accelerate the execution of EyePoint's pipeline and clinical trials.
• The press release highlights the positive interim data for the Phase 2 trial in diabetic macular edema, indicating progress in the company's developmental efforts.
• Emphasis on the potential revolutionary treatments for serious retinal diseases may enhance investor confidence in EyePoint's product candidates and future growth.

Potential Negatives

• Appointment of Dr. Reginald J. Sanders may highlight a lack of existing leadership strength in the organization, suggesting previous gaps in expertise or direction.
• FDA approval for DURAVYU remains uncertain, which could negatively impact investor confidence and the company’s stock performance.
• Forward-looking statements reveal several risks, including potential delays in clinical trials and the need for additional funding, raising concerns about the company's financial health and operational stability.

FAQ

Who is Reginald J. Sanders, M.D.?

Reginald J. Sanders, M.D. is a distinguished leader in ophthalmology and the newest member of EyePoint's Board of Directors.

What experience does Dr. Sanders bring to EyePoint Pharmaceuticals?

Dr. Sanders brings unparalleled clinical experience and a background in business development within the retina community, critical for EyePoint's goals.

What is EyePoint Pharmaceuticals focused on?

EyePoint Pharmaceuticals is focused on developing innovative therapeutics to improve the lives of patients suffering from serious retinal diseases.

What is DURAVYU and its significance?

DURAVYU is EyePoint's investigational product for treating VEGF-mediated retinal diseases, currently in Phase 3 trials for wet AMD.

When can we expect clinical data for EyePoint's trials?

Full topline data from the Phase 2 trial in diabetic macular edema is expected in Q1 2025, with wet AMD data in 2026.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$EYPT Insider Trading Activity

$EYPT insiders have traded $EYPT stock on the open market 5 times in the past 6 months. Of those trades, 4 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $EYPT stock by insiders over the last 6 months:

• GORAN ANDO purchased 5,000 shares.
• WENDY F DICICCO purchased 2,567 shares.
• KAREN L. ZADEREJ purchased 12,500 shares.
• NANCY LURKER purchased 3,173 shares.
• DAVID R GUYER sold 11,625 shares.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$EYPT Hedge Fund Activity

We have seen 70 institutional investors add shares of $EYPT stock to their portfolio, and 78 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• FEDERATED HERMES, INC. added 1,633,468 shares (+562.9%) to their portfolio in Q3 2024
• PATIENT SQUARE CAPITAL LP added 1,361,979 shares (+inf%) to their portfolio in Q3 2024
• 5AM VENTURE MANAGEMENT, LLC added 1,000,000 shares (+2000.0%) to their portfolio in Q3 2024
• AMERIPRISE FINANCIAL INC removed 897,032 shares (-97.3%) from their portfolio in Q3 2024
• DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 877,790 shares (-100.0%) from their portfolio in Q3 2024
• T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 802,809 shares (-38.8%) from their portfolio in Q3 2024
• FIERA CAPITAL CORP removed 677,038 shares (-100.0%) from their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors.

“I am pleased to welcome Dr. Sanders to EyePoint’s Board,” said Göran Ando, M.D., Chair of the Board of Directors of EyePoint. “Scientific and medical leadership underpin our mission to develop innovative therapeutics for patients with serious retinal diseases, and as a prominent leader in the retina community, Dr. Sanders will be an invaluable addition to our Board. With our global phase 3 pivotal trials for wet AMD underway and the recent positive interim data for our Phase 2 trial in diabetic macular edema, Dr. Sanders’ unparalleled clinical experience and unique experience of business development in the retina space will be critical as we continue to execute across our pipeline.”

“It is an honor to join the EyePoint Board of Directors at this important time,” said Dr. Sanders. “I have dedicated my career to providing the highest quality of comprehensive care to my patients by being on the cutting-edge of innovation in retina research. I am impressed by EyePoint’s robust clinical data and significant potential of DURAVYU for serious retinal diseases. The EyePoint team has a track record of excellence in execution, and I look forward to working closely with the talented management team and the Board as they continue to work to bring potential revolutionary treatments to patients.”

Dr. Sanders is a distinguished retina specialist currently serving as a board member of Prism Vision Group (PVG), and he is the most recent President of the American Society of Retina Specialists (ASRS). Dr. Sanders is also a physician within the Retina Group of Washington (RGW), a division of PVG. He served many years as president and managing partner of RGW and was a main driver in building RGW to become the largest practice of retinal specialists in the United States. Dr. Sanders has a career in education and research with RGW, developing a national reputation. He is well published, having more than 50 papers, articles and presentations to his credit, and has lectured nationally and abroad. Dr. Sanders has served as an investigator/sub-investigator in numerous studies of new retinal treatments, including being a principal investigator for Lucentis

^®

, a landmark treatment for wet age-related macular degeneration (wet AMD).

Dr. Sanders has made significant contributions to ophthalmology demonstrated by a collection of honors and awards. His exceptional achievements include his election as a charter inductee into the Retina Hall of Fame, receipt of the Packo Service Award in recognition of his exceptional service to the Society. He trained at Yale-New Haven Hospital and Wills Eye Hospital in Philadelphia, and he completed a fellowship in Vitreo-retinal Diseases and Surgery at the Massachusetts Eye and Ear Infirmary/Harvard Medical School. Dr. Sanders holds an M.D. from Yale University and a B.S. from the University of Virginia.

About EyePoint Pharmaceuticals

EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E

^™

technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU

^™

(f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E

^™

. DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in diabetic macular edema (DME). EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026.

Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E

^™

to potentially improve outcomes in serious retinal diseases. The proven Durasert

^®

drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Forward Looking Statements

EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our expectations regarding the timing and clinical development and potential of DURAVYU in wet AMD and DME, including our expectations regarding the announcement of full topline data from the VERONA trial in the first quarter of 2025 and initiation of the LUGANO trial and the LUCIA trial; the belief that the interim results from the VERONA trial support DURAVYU’s potential to advance to non-inferiority pivotal trials; our beliefs and expectations regarding the anticipated full results from the VERONA trial; the potential for DURAVYU 2.7mg to extend treatment intervals while improving vision; the potential for DURAVYU to provide an immediate benefit over aflibercept control in both BCVA and CST; our optimism that that DURAVYU has the potential to shift the treatment paradigm in DME and improve patient outcomes; our expectations regarding clinical development of our other product candidates, including EYP-2301; our business strategies and objectives; and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the company’s clinical development activities; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; the company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the company’s product candidates; changes in the regulatory environment; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates; the availability of and the need for additional financing; the company’s ability to obtain additional funding to support its clinical development programs; uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney’s Office for the District of Massachusetts; uncertainties regarding the FDA warning letter pertaining to the company’s Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investors:

Christina Tartaglia


Precision AQ


Direct: 212-698-8700



christina.tartaglia@sternir.com

Media Contact:

Amy Phillips


Green Room Communications


Direct: 412-327-9499



aphillips@greenroompr.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.